Lithuania-based Sentante, a member of the EIC Scaling Club’s Health Tech market group, is working to change how endovascular procedures are performed.
Developed by Inovatyvi Medicina, the company’s teleoperated robotic system enables physicians to carry out vascular interventions from a remote workstation, while a bedside robotic unit manipulates standard guidewires and catheters at the patient’s side.
Endovascular medicine is used to treat serious cardiovascular and neurovascular conditions, including stroke, heart attacks and peripheral artery disease. These procedures often require physicians to stand close to X-ray imaging equipment for long periods, wearing heavy lead aprons while manually navigating devices through the vascular system.
Sentante’s platform is designed to address several of these constraints at once. The physician controls the procedure from an X-ray-free environment, using a remote workstation with visualisation tools and haptic force feedback. The bedside unit then translates the physician’s hand movements into real-time robotic manipulation of guidewires and catheters.
This is where Sentante’s core differentiator lies. The company has built its platform around an intuitive, tactile interface that aims to preserve the feel of manual intervention while adding robotic precision, stability and digital control.
Instead of asking clinicians to adapt to a joystick-based system, Sentante’s approach is designed to replicate the familiar hand movements used in conventional procedures.
The result is a system intended to protect staff from radiation exposure and physical strain, support procedural consistency, and make better use of scarce clinical expertise. It is also designed to work with existing hospital infrastructure, clinical workflows and procedure consumables, which could make adoption easier for hospitals already equipped for endovascular care.
Sentante’s mission is to make life-saving vascular interventions more widely accessible by combining mechatronics, sensor technology, digital data, artificial intelligence and connectivity.
That mission is especially relevant in time-critical stroke care.
Mechanical thrombectomy can be highly effective for certain patients with acute ischaemic stroke, but access often depends on geography, and transfer delays can have lasting consequences.
Sentante’s remote robotics platform is being developed with this access gap in mind. In the near term, the system can allow clinicians to operate from a control room next to the procedure room.
Over time, the same principle could support procedures performed from another building, another hospital or another city, subject to regulatory approval, clinical validation and the necessary connectivity infrastructure.
Sentante was founded in 2017 and is based in Kaunas, Lithuania. The company was co-founded by Edvardas Satkauskas, who serves as chief executive officer, and Dr Tomas Baltrūnas, who serves as chief medical officer.
Sentante’s team brings together engineers, clinicians, researchers and operators. This multidisciplinary model is important in medical robotics, where success depends not only on a working prototype, but on usability, safety, regulatory readiness and integration into real hospital workflows.
The leadership team has also helped frame Sentante’s technology around three practical priorities: access for patients, safety for clinicians and compatibility with the way hospitals already work. In a field where adoption can be slowed by complexity, this focus on clinical reality may prove as important as the robotic system itself.
Sentante has reached several key milestones in recent years.
In December 2023, the company raised €6 million in seed funding led by Practica Capital, with participation from the EIC Fund, to support clinical trials and prepare for commercial launch.
Since then, Sentante has progressed through regulatory and technical validation, including a clinical trial in peripheral vascular interventions and pre-clinical work in remote stroke treatment.
In 2025, the company demonstrated a transatlantic remote robotic stroke intervention, highlighting the potential for remote neurovascular procedures, while acknowledging the need for further validation and regulatory approval.
That same year, the Sentante Stroke System received FDA Breakthrough Device Designation. In February 2026, it was accepted into the FDA’s Total Product Life Cycle Advisory Program.
In May 2026, Sentante achieved CE mark approval for its endovascular robotic platform, enabling commercialisation across European markets.
Sentante’s progress reflects both the promise and the difficulty of building medical robotics for endovascular care.
The technology must be precise enough for delicate vascular procedures, intuitive enough for experienced clinicians, compatible with existing tools, and robust enough for real clinical environments. It must also meet high regulatory standards and generate the evidence needed for adoption by hospitals and healthcare systems.
The company has addressed these challenges by focusing on a platform that mirrors manual procedure techniques, works with conventional endovascular devices and prioritises tactile feedback. This approach could help reduce the adoption barrier for clinicians, while still creating the digital foundation for future assistance, training and data-driven improvement.
The EIC Scaling Club is a curated community where 120+ European deep tech scale-ups with the potential to build world-class businesses and solve major global challenges come together with investors, corporate innovators and other industry stakeholders to spur growth.
The top 120+ European deep tech companies will be carefully selected from a pool of high-growth scale-ups that have benefitted from EIC financial schemes, other European and national innovation programmes, and beyond.
The EIC Scaling Club is an EIC-funded initiative run in partnership by Tech Tour, Bpifrance (EuroQuity), Hello Tomorrow, Tech.eu (Webrazzi), EurA and IESE Business School.
Subscribe to our newsletter here to stay up-to-date!